恩替卡韦治疗慢性重型乙型肝炎48例临床观察

目的] 探讨恩替卡韦治疗慢性重型乙型肝炎的近期疗效和安全性.方法]48例HBV DNA阳性的慢性重型乙型肝炎在综合治疗的基础上,使用恩替卡韦0.5 mg,每晚口服1次,对照组42例为常规综合治疗.结果]恩替卡韦治疗组HBV DNA阴转率81.25%,临床有效率75%;对照组HBV DNA阴转率21.43%,临床有效率50%.治疗组好转率明显高于对照组,差异有非常显著性（P＜0.05）.结论]在综合治疗的基础上,应用恩替卡韦治疗慢性重型乙型肝炎可改善患者临床症状,提高生存率,降低病死率.

Clinical Observation of Entecavir for the Treatment of 48 Patients with Chronic Hepatitis Gravis B

Objective]To explore the short-term efficacy and safety of entecavir for the treatment of chronic hepatitis gravis B. Results] Totally 48 cases of chronic hepatic gravis B with positive HBV DNA were given oral entecavir 0.5mg once a night based on the synthetic therapy. The control group（ n = 42） received routine synthetic treatment only. Results] In entecavir treatment group, the negative rate of H]3V DNA was 81.25% and the clinical effective rate was 75%. In control group, the negative rate of HBV DNA was 21.43% and the clinical effective rate was 50%. The remission rate of entecavir treatment group was obviously higher that of control group, and there was very significant difference （ P〈0.05）. Conclusion] Entecavir based on synthesis therapy for the treatment of chronic hepatitis gravis B can improve clinical symptoms of patients, increase the survival rate and reduce the fatality rate.